DOP2013000087A - Formulacion de capsula - Google Patents
Formulacion de capsulaInfo
- Publication number
- DOP2013000087A DOP2013000087A DO2013000087A DO2013000087A DOP2013000087A DO P2013000087 A DOP2013000087 A DO P2013000087A DO 2013000087 A DO2013000087 A DO 2013000087A DO 2013000087 A DO2013000087 A DO 2013000087A DO P2013000087 A DOP2013000087 A DO P2013000087A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- ingredient
- liquids
- capsule
- liquid
- pharmaceutically
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La pres ent e inv enc ión pro po rc iona la sigui ent e preparación de cáps ula, qu e es s upe r io r en la carac ter íst ic a de dis oluc ión y simi lares de un ingredient e farmac éut ic ament e act iv o y c ont ien e los ingredientes farmac éut ic amente a ct iv os l íq uidos y s ól id os : una cápsula t rans p ar ente qu e c ont ien e los ingred ient es farmac é ut ic ame nte ac t iv os l íquidos y s ól idos , en donde el ingrediente l íq uido farmac éut ic amente ac t iv o s e enc aps ula en forma d e c omposi c ió n f armac éut i ca l íquid a, y el ingredi ente s ól ido farmac é ut ic ame nte ac t i vo s e di spe rsa en una cap a de c ubier t a de cápsula.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008003634 | 2008-01-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2013000087A true DOP2013000087A (es) | 2014-01-31 |
Family
ID=40853060
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2010000214A DOP2010000214A (es) | 2008-01-10 | 2010-07-09 | Formulacion de capsula |
DO2013000087A DOP2013000087A (es) | 2008-01-10 | 2013-04-19 | Formulacion de capsula |
DO2013000085A DOP2013000085A (es) | 2008-01-10 | 2013-04-19 | Formulacion de capsula |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2010000214A DOP2010000214A (es) | 2008-01-10 | 2010-07-09 | Formulacion de capsula |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2013000085A DOP2013000085A (es) | 2008-01-10 | 2013-04-19 | Formulacion de capsula |
Country Status (21)
Country | Link |
---|---|
US (1) | US20100285121A1 (es) |
EP (3) | EP2455070A1 (es) |
JP (1) | JP5421126B2 (es) |
KR (1) | KR20100111292A (es) |
CN (3) | CN103705487A (es) |
AU (1) | AU2008345848B2 (es) |
BR (1) | BRPI0822019A2 (es) |
CA (1) | CA2711814A1 (es) |
CO (1) | CO6290641A2 (es) |
CR (1) | CR11625A (es) |
DO (3) | DOP2010000214A (es) |
EA (3) | EA201070835A1 (es) |
EC (1) | ECSP10010395A (es) |
IL (1) | IL206791A0 (es) |
MA (1) | MA32027B1 (es) |
MX (1) | MX2010007609A (es) |
MY (1) | MY157189A (es) |
NZ (3) | NZ587019A (es) |
UA (3) | UA100403C2 (es) |
WO (1) | WO2009087938A1 (es) |
ZA (1) | ZA201004793B (es) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2334295B1 (en) | 2008-09-02 | 2017-06-28 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same |
ITFI20080243A1 (it) * | 2008-12-15 | 2010-06-16 | Valpharma Sa | Formulazioni per la somministrazione orale di acidi grassi omega polienoici in combinazione con statine di origine naturale o semi-sintetica. |
PH12019500030A1 (en) | 2009-03-09 | 2020-02-10 | Pronova Biopharma Norge As | Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof |
EP3278665B1 (en) | 2009-04-29 | 2020-09-09 | Amarin Pharmaceuticals Ireland Limited | Stable pharmaceutical composition and methods of using same |
AU2010241567B2 (en) | 2009-04-29 | 2013-10-31 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same |
CN108096209A (zh) | 2009-06-15 | 2018-06-01 | 阿马里纳制药公司 | 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法 |
KR101798670B1 (ko) | 2009-09-23 | 2017-11-16 | 아마린 코포레이션 피엘씨 | 오메가-3 지방산 및 스타틴의 히드록시-유도체를 포함하는 제약 조성물 및 그의 사용 방법 |
KR20200013123A (ko) * | 2009-10-23 | 2020-02-05 | 바스프 에이에스 | 지방산 오일 혼합물의 코팅된 캡슐 및 정제 |
ES2364011B1 (es) * | 2009-11-20 | 2013-01-24 | Gp Pharm, S.A. | Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares. |
CA3065589C (en) * | 2010-06-03 | 2022-04-26 | Catalent Ontario Limited | Multi phase soft gel capsules, apparatus and method thereof |
CA2706270C (en) * | 2010-06-03 | 2020-01-07 | Accucaps Industries Limited | Pharmaceutical formulations of statins and omega-3 fatty acids for encapsulation |
WO2012002464A1 (ja) | 2010-06-30 | 2012-01-05 | 持田製薬株式会社 | ω3脂肪酸の配合製剤 |
NZ611606A (en) | 2010-11-29 | 2015-10-30 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US8715648B2 (en) * | 2011-02-16 | 2014-05-06 | Pivotal Therapeutics Inc. | Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics |
KR101310710B1 (ko) * | 2011-03-23 | 2013-09-27 | 한미약품 주식회사 | 오메가-3 지방산 에스테르 및 HMG-CoA 환원효소 억제제를 포함하는 경구용 복합 조성물 |
JP5876695B2 (ja) * | 2011-09-29 | 2016-03-02 | 森下仁丹株式会社 | シームレスカプセルおよびその製造方法 |
EP2775837A4 (en) | 2011-11-07 | 2015-10-28 | Amarin Pharmaceuticals Ie Ltd | METHODS OF TREATING HYPERTRIGLYCERIDEMIA |
US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
KR101466617B1 (ko) * | 2011-11-17 | 2014-11-28 | 한미약품 주식회사 | 오메가-3 지방산 및 HMG-CoA 환원효소 억제제를 포함하는 안정성이 증가된 경구용 복합 제제 |
AU2013207368A1 (en) | 2012-01-06 | 2014-07-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity (hs-CRP) in a subject |
WO2013103902A1 (en) | 2012-01-06 | 2013-07-11 | Omthera Pharmaceuticals, Inc. | Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form |
EP2846779A4 (en) * | 2012-05-07 | 2015-12-16 | Omthera Pharmaceuticals Inc | STATIN AND OMEGA-3 FATTY ACID COMPOSITIONS |
RU2600804C2 (ru) | 2012-05-22 | 2016-10-27 | Кухниль Фарм. Ко., Лтд. | Форма многослойного покрытия фармацевтической композиции для перорального применения, содержащей омега-3 жирную кислоту или ее алкиловый сложный эфир, а также лекарственное средство на основе статина |
KR20150036252A (ko) | 2012-06-29 | 2015-04-07 | 애머린 파마슈티칼스 아일랜드 리미티드 | 스타틴 요법 중인 대상체에서 심혈관 사건의 위험을 감소시키는 방법 |
CN102824640A (zh) * | 2012-08-06 | 2012-12-19 | 济南圣泉唐和唐生物科技有限公司 | 一种胶囊壳及其制备方法 |
US20150265566A1 (en) | 2012-11-06 | 2015-09-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy |
US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
WO2014134466A1 (en) * | 2013-03-01 | 2014-09-04 | Amarin Pharmaceuticals Ireland Limited. | Co-administration of atorvastatin and ethyl eicosapentaenoic acid or a derivative thereof |
US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
US20140271841A1 (en) * | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
CA2937666A1 (en) * | 2014-01-31 | 2015-08-06 | Morishita Jintan Co., Ltd. | Orally administered agent for ruminants and ruminant feed containing same |
US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
US10172818B2 (en) | 2014-06-16 | 2019-01-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
US10278898B2 (en) * | 2014-06-26 | 2019-05-07 | R.P. Scherer Technologies, Llc | Methods for manufacturing encapsulated granular material, methods for drying coating materials, and fluidized bed dryers |
MA41611A (fr) | 2015-02-23 | 2018-01-02 | Omthera Pharmaceuticals Inc | Préparations en milli-capsules comprenant des acides gras polyinsaturés libres |
CN104940654A (zh) * | 2015-06-24 | 2015-09-30 | 黄红林 | 一种葛根胶囊 |
KR101950907B1 (ko) * | 2016-02-05 | 2019-02-21 | 한국유나이티드제약 주식회사 | 지용성 약물 및 방유성 기제가 코팅된 고형제제를 포함하는 경구용 복합제제 |
US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
US10966951B2 (en) | 2017-05-19 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
CN107422021B (zh) * | 2017-07-14 | 2019-11-19 | 北京朗阅科技有限公司 | 琼脂糖胶囊及其制备方法与应用 |
US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
US20210137917A1 (en) * | 2018-04-09 | 2021-05-13 | Intas Pharmaceuticals Ltd. | Pharmaceutical composition of nintedanib esylate |
EP3750536A1 (en) | 2018-09-24 | 2020-12-16 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of cardiovascular events in a subject |
US11986452B2 (en) | 2021-04-21 | 2024-05-21 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5488880A (en) * | 1977-10-06 | 1979-07-14 | Eru Emu Asoshieito Yuugen | Soft capsule |
US4444784A (en) * | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
JPS5953410A (ja) * | 1982-09-20 | 1984-03-28 | Fujisawa Pharmaceut Co Ltd | 新型ソフトカプセル剤 |
JPS59157018A (ja) * | 1983-02-27 | 1984-09-06 | Furointo Sangyo Kk | 新規なる被覆含油カプセル剤形 |
GB8305693D0 (en) * | 1983-03-02 | 1983-04-07 | Scherer Ltd R P | Pharmaceutical compositions |
JPS63238015A (ja) * | 1987-03-24 | 1988-10-04 | Morishita Jintan Kk | 徐放性カプセル製剤 |
JPH01186815A (ja) * | 1988-01-21 | 1989-07-26 | Tokai Kapuseru Kk | 軟カプセル剤およびその製造法 |
JPH01193216A (ja) * | 1988-01-29 | 1989-08-03 | Fuji Kapuseru Kk | ソフトカプセル及び球状物 |
GB8819110D0 (en) | 1988-08-11 | 1988-09-14 | Norsk Hydro As | Antihypertensive drug & method for production |
FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
JP3159724B2 (ja) * | 1991-04-19 | 2001-04-23 | フロイント産業株式会社 | シームレスカプセル製造方法および装置 |
JP3144865B2 (ja) * | 1991-12-06 | 2001-03-12 | エーザイ株式会社 | 軟カプセル剤 |
JPH0753356A (ja) * | 1993-08-16 | 1995-02-28 | Morishita Jintan Kk | 酸化され易い油性物質を内容物とするシームレスカプセルおよびその製造方法 |
JPH0823912A (ja) * | 1994-07-19 | 1996-01-30 | Yoshinobu Umeda | アシタバ入り食品 |
US5650232A (en) | 1994-10-07 | 1997-07-22 | Warner-Lambert Company | Method for making seamless capsules |
US5641512A (en) * | 1995-03-29 | 1997-06-24 | The Procter & Gamble Company | Soft gelatin capsule compositions |
AU6944296A (en) | 1995-09-13 | 1997-04-01 | Takeda Chemical Industries Ltd. | Benzoxazepine compounds, their production and use as lipid lowering agents |
GB9706149D0 (en) * | 1997-03-25 | 1997-05-14 | Scherer Corp R P | Comestible capsules having flavoured coatings |
KR100569319B1 (ko) * | 1997-10-30 | 2006-04-07 | 모리시타 진탄 가부시키가이샤 | 불포화 지방산 또는 이들의 유도체를 내용물로 하는 캡슐제제 및 그의 제조방법 |
GB9916536D0 (en) * | 1999-07-14 | 1999-09-15 | Scarista Limited | Nutritional or pharmaceutical compositions |
AR035016A1 (es) | 1999-08-25 | 2004-04-14 | Takeda Chemical Industries Ltd | Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima. |
ATE479429T1 (de) | 2000-04-28 | 2010-09-15 | Takeda Pharmaceutical | Antagonisten des melanin-konzentrierenden hormons |
EP1283199A4 (en) | 2000-05-16 | 2003-12-17 | Takeda Chemical Industries Ltd | MELANIN CONCENTRATION HORMONE ANTAGONIST |
GB0011838D0 (en) | 2000-05-17 | 2000-07-05 | Astrazeneca Ab | Chemical compounds |
AU2003231439A1 (en) * | 2002-05-09 | 2003-11-11 | Chugai Seiyaku Kabushiki Kaisha | Photostabilized soft capsule |
KR100490279B1 (ko) * | 2002-07-18 | 2005-05-17 | 주식회사 서흥캅셀 | 구취제거 및 구강 청량 효과를 지닌 젤라틴 연질캅셀제 |
CA2529735C (en) * | 2003-06-20 | 2012-07-10 | Mochida Pharmaceutical Co., Ltd. | Eicosapentaenoic acid for preventing or treating varicose veins of lower extremities |
JP2005046054A (ja) * | 2003-07-29 | 2005-02-24 | Nippon Kayaku Co Ltd | ダイエット食品及びダイエット用製剤 |
DE102004019916A1 (de) * | 2004-04-21 | 2005-11-17 | Grünenthal GmbH | Gegen Missbrauch gesichertes wirkstoffhaltiges Pflaster |
CA2563680A1 (en) * | 2004-04-21 | 2005-11-03 | Kyowa Hakko Kogyo Co., Ltd. | Seamless capsule containing water-soluble active substance |
ES2255426B1 (es) * | 2004-10-19 | 2007-08-16 | Gp Pharm, S.A. | Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa). |
EP1834639B8 (en) * | 2005-01-04 | 2016-12-07 | Mochida Pharmaceutical Co., Ltd. | Remedial agent for fat toxicity |
WO2006104703A1 (en) * | 2005-03-29 | 2006-10-05 | Mcneil-Ppc, Inc. | Compositions with hydrophilic drugs in a hydrophobic medium |
AR054368A1 (es) * | 2005-06-01 | 2007-06-20 | Takeda Pharmaceutical | Metodo para tratar hiperlipidemia |
JP4327872B2 (ja) | 2005-10-07 | 2009-09-09 | トヨタ自動車株式会社 | 複数枚の回路基板を固定する固定部材とそれを利用したモジュール |
JP4005104B2 (ja) * | 2006-02-07 | 2007-11-07 | 持田製薬株式会社 | 脳卒中再発予防用組成物 |
EP1982710B1 (en) * | 2006-02-07 | 2013-12-18 | Mochida Pharmaceutical Co., Ltd. | Composition for prevention of recurrence of stroke |
EP2081550B2 (en) * | 2006-03-09 | 2021-05-26 | Reliant Pharmaceuticals, Inc. | Coating capsules with active pharmaceutical ingredients |
US8784886B2 (en) * | 2006-03-09 | 2014-07-22 | GlaxoSmithKline, LLC | Coating capsules with active pharmaceutical ingredients |
JP2009541433A (ja) * | 2006-06-26 | 2009-11-26 | ヴァルファルマ ソチエタ アノニマ | オメガポリエン脂肪酸の経口投与のための医薬品の組成物、及び1又はそれ以上の配合禁忌の有効成分、並びにその調剤の工程 |
EP2119443B1 (en) * | 2007-01-17 | 2014-08-20 | Mochida Pharmaceutical Co., Ltd. | Composition for prevention or treatment of disease associated with thrombus or embolus |
CN102552213A (zh) * | 2007-06-29 | 2012-07-11 | 武田药品工业株式会社 | 无缝胶囊 |
-
2008
- 2008-12-29 UA UAA201009902A patent/UA100403C2/ru unknown
- 2008-12-29 EA EA201070835A patent/EA201070835A1/ru unknown
- 2008-12-29 EP EP12155487A patent/EP2455070A1/en not_active Withdrawn
- 2008-12-29 BR BRPI0822019-0A patent/BRPI0822019A2/pt not_active IP Right Cessation
- 2008-12-29 US US12/735,383 patent/US20100285121A1/en not_active Abandoned
- 2008-12-29 CN CN201310750786.4A patent/CN103705487A/zh active Pending
- 2008-12-29 WO PCT/JP2008/073875 patent/WO2009087938A1/ja active Application Filing
- 2008-12-29 EA EA201200830A patent/EA201200830A1/ru unknown
- 2008-12-29 MX MX2010007609A patent/MX2010007609A/es not_active Application Discontinuation
- 2008-12-29 AU AU2008345848A patent/AU2008345848B2/en not_active Expired - Fee Related
- 2008-12-29 CN CN201310750781.1A patent/CN103705486A/zh active Pending
- 2008-12-29 KR KR1020107017646A patent/KR20100111292A/ko not_active Application Discontinuation
- 2008-12-29 MY MYPI2010003285A patent/MY157189A/en unknown
- 2008-12-29 NZ NZ587019A patent/NZ587019A/en not_active IP Right Cessation
- 2008-12-29 CN CN200880127958XA patent/CN101969932A/zh active Pending
- 2008-12-29 UA UAA201205712A patent/UA102478C2/ru unknown
- 2008-12-29 EP EP08870164A patent/EP2229939A4/en not_active Withdrawn
- 2008-12-29 NZ NZ600721A patent/NZ600721A/xx not_active IP Right Cessation
- 2008-12-29 NZ NZ600720A patent/NZ600720A/xx not_active IP Right Cessation
- 2008-12-29 JP JP2009548895A patent/JP5421126B2/ja not_active Expired - Fee Related
- 2008-12-29 EP EP12155560A patent/EP2455071A1/en not_active Withdrawn
- 2008-12-29 UA UAA201205711A patent/UA102477C2/ru unknown
- 2008-12-29 EA EA201200829A patent/EA201200829A1/ru unknown
- 2008-12-29 CA CA2711814A patent/CA2711814A1/en not_active Abandoned
-
2010
- 2010-07-04 IL IL206791A patent/IL206791A0/en unknown
- 2010-07-07 ZA ZA2010/04793A patent/ZA201004793B/en unknown
- 2010-07-09 DO DO2010000214A patent/DOP2010000214A/es unknown
- 2010-07-16 MA MA33030A patent/MA32027B1/fr unknown
- 2010-08-10 CR CR11625A patent/CR11625A/es not_active Application Discontinuation
- 2010-08-10 CO CO10098064A patent/CO6290641A2/es not_active Application Discontinuation
- 2010-08-10 EC EC2010010395A patent/ECSP10010395A/es unknown
-
2013
- 2013-04-19 DO DO2013000087A patent/DOP2013000087A/es unknown
- 2013-04-19 DO DO2013000085A patent/DOP2013000085A/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2013000087A (es) | Formulacion de capsula | |
CL2019000431A1 (es) | Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos. (divisional solicitud 201700814) | |
CO2018003424A2 (es) | Composición farmacéutica y formulación de inyección subcutánea que comprende micelas y curcuminoides para reducir la grasa localizada y método para preparar la misma” | |
AR052031A1 (es) | Composicon oftalmica que comprende un componente portador acuoso y una cantidad efectiva de un componente de tonicidad, su uso para preparar un medicamento y uso de un componente portador y una cantidad efectiva de un componente polianionico para preparar dicha composicion | |
DK1902026T3 (da) | Tetrahydrocarbazol-derivater, der kan anvendes som androgen-receptor-modulatorer (SARM) | |
BR112014031837A2 (pt) | formulações de progesterona | |
NZ603686A (en) | Topical formulation for a jak inhibitor | |
ECSP11011243A (es) | Agonistas y antagonistas de los receptores s1p5 y metodos de usos similares aplicaciones relacionadas | |
CL2008000981A1 (es) | Compuestos derivados de imidazolidin-carboxamida; composicion farmaceutica; procedimiento de produccion de la composicion farmaceutica; y uso en el tratamiento y/o prevencion de trastornos ateroscleroticos, de metabolismo de acidos grasos y en los qu | |
AR087177A1 (es) | Formulacion de una capsula que comprende montelukast y levocetirizina | |
CL2018003319A1 (es) | Compuestos de mic-1 y usos de estos. | |
HN2008001666A (es) | Derivados acidos de cicloalquilamino | |
AR105237A1 (es) | Método y composiciones nutricionales que contienen fosfatidiletanolamina, esfingomielina y ácido docosahexaenoico | |
CL2012000261A1 (es) | Composición farmacéutica líquida de ácido 4- {[9-cloro-7-(2-fluoro-6-metoxifenil)-5h-pirimido[5,4-d][2]benzazepin-2-il]amino}-2-metoxibenzoico en una mezcla de disolventes con al menos 15% de propilenglicol, 15% de peg400 y menos de 50% de agua; y su uso para la preparación de un medicamento para el tratamiento de cáncer. | |
CL2019003441A1 (es) | Puestos de mic-1 y usos de estos. | |
ES2405531R1 (es) | Formulaciones sólidas y su uso en el mantenimiento de la salud gastrointestinal | |
RU2017129161A (ru) | Композиции липидов | |
GT200800235A (es) | Formulacion de medicamento liquida | |
PE20050414A1 (es) | Formulacion farmaceutica oral que comprende un antagonista de la bomba de protones y un excipiente basico | |
CN106456598B (zh) | 外用药物组合物 | |
AR076916A1 (es) | Medicamento a base de calcio y de vitamina d. kit. | |
ECSP099650A (es) | Composiciones farmacéuticas sinergicas que comprenden la combinacion de un inhibidor de la enzima 5 -reductasa y un antagonista de los receptores 1 -adrenergicos | |
GT200700005A (es) | Composicion farmaceutica estable de carisoprodol y meloxicam | |
TWI673050B (zh) | 外用醫藥組成物 | |
US8501201B1 (en) | Composition useful for improving skin |